Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6Clo monocytes that mediates resistance to anti-VEGFR2 treatment. We found that the chemokine CX3CL1 was upregulated in both human and murine tumors following VEGF signaling blockade, resulting in recruitment of CX3CR1+Ly6Clo monocytes into the tumor. We also found that treatment with VEGFA reduced expression of CX3CL1 in endothelial cells in vitro. Intravital microscopy revealed that CX3CR1 is critical for Ly6Clo monocyte transmigration across the endothelium in murine CRC tumors. Moreover, Ly6Clo monocytes recruit Ly6G+ neutrophils via CXCL5 and produce IL-10, which inhibits adaptive immunity. Preventing Ly6Clo monocyte or Ly6G+ neutrophil infiltration into tumors enhanced inhibition of tumor growth with anti-VEGFR2 therapy. Furthermore, a gene therapy using a nanoparticle formulated with an siRNA against CX3CL1 reduced Ly6Clo monocyte recruitment and improved outcome of anti-VEGFR2 therapy in mouse CRCs. Our study unveils an immunosuppressive function of Ly6Clo monocytes that, to our knowledge, has yet to be reported in any context. We also reveal molecular mechanisms underlying antiangiogenic treatment resistance, suggesting potential immunomodulatory strategies to enhance the long-term clinical outcome of anti-VEGF therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“emerging data suggest that immunosuppression, in turn, contributes to resistance to antiangiogenesis treatments37–39,41”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“In mouse models of CRC, high-dose anti-VEGF treatment can also result in the recruitment of immunosuppressive, nonclassical, lymphocyte antigen 6C (Ly6C)low monocytes that also confer resistance to anti-VEGF therapy, thus setting up a vicious cycle38,39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“These cells display a high level of CX3CR1, while Ly6Chi monocytes and Ly6G+ neutrophils (hereafter referred to as neutrophils) express CCR2 and CXCR2, respectively (25, 39, 44) (Supplemental Figure 2B).”
BackgroundBlood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties
Geissmann, F., Jung, S., & Littman, D. R. (2003) · Immunity · doi:10.1016/s1074-7613(03)00174-2 · Cited by 3,391
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“, CX3CR1 on Ly6Clo monocytes, CCR2 on Ly6Chi monocytes) (32, 59) (Supplemental Figure 2B).”
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Cited by
Items 101–164 of 164
Patrolling Monocytes Are Recruited and Activated by Diabetes to Protect Retinal Microvessels
Tecilazich, F., Phan, T. A., Simeoni, F., Scotti, G. M., Dagher, Z., & Lorenzi, M. (2020) · Diabetes · doi:10.2337/db19-1043 · Cited by 20
Advance of nano anticancer therapies targeted on tumor-associated macrophages
Wang, M., Zhao, J., Xiong, H., Lu, H., Jiang, H., & Wang, X. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214126 · Cited by 15
Blaye, C., Boyer, T., Peyraud, F., Domblides, C., & Larmonier, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.838040 · Cited by 16
Hu, J., Wang, Z., Chen, Z., Li, A., Sun, J. P., Zheng, M., Wu, J., Shen, T., Qiao, J., Li, L., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110229 · Cited by 15
Jeong, J., Kim, D. K., Park, J., Park, D. J., Lee, H., Yang, H., Kong, S., & Jung, K. (2021) · Immune Network · doi:10.4110/in.2021.21.e31 · Cited by 14
Self-citationApplications of Intravital Imaging in Cancer Immunotherapy
Deng, D., Hao, T., Lu, L., Yang, M., Zeng, Z., Lovell, J. F., Liu, Y., & Jin, H. (2024) · Bioengineering · doi:10.3390/bioengineering11030264 · Cited by 13
Role of Tumor-Associated Macrophages in Breast Cancer Immunotherapy
He, Y., Liu, Q., Luo, Z., Hu, Q., Wang, L., & Guo, Z. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26995 · Cited by 15
6′-Sialylgalactose inhibits vascular endothelial growth factor receptor 2-mediated angiogenesis
Chung, T., Kim, E.-Y., Choi, H., Han, C. W., Jang, S. B., Kim, K., Jin, L., Koh, Y. J., & Ha, K. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0311-6 · Cited by 15
Mougel, A., Méjean, F., Tran, T., Adimi, Y., Galy–Fauroux, I., Kaboré, C., Mercier, E., Urquia, P., Terme, M., Tartour, É., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2110218 · Cited by 12
Xu, Y., Zhang, X., Wang, Y., Pan, M., Wang, M., & Zhang, J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02379-9 · Cited by 12
Federico, P., Giunta, E. F., Tufo, A., Tovoli, F., Petrillo, A., & Daniele, B. (2022) · Cancers · doi:10.3390/cancers14246245 · Cited by 11
Tran, T., Lavillegrand, J., Lerévérend, C., Esposito, B., Cartier, L., Montabord, M., Tran-Rajau, J., Diedisheim, M., Gruel, N., Ouguerram, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33034-0 · Cited by 16
Xu, Q., Chen, J., Ye, W., Zhang, C., Wang, D., Wei, W., & Hu, S. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175466 · Cited by 10
Cellular Plasticity during Metastasis: New Insights Provided by Intravital Microscopy
Margarido, A. S., Bornes, L., Vennin, C., & van Rheenen, J. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037267 · Cited by 9
Ball, D., Nault, J., Vithayathil, M. K., Allaire, M., Ganne‐Carrié, N., Campani, C., Marra, F., & Sharma, R. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00908-7 · Cited by 8
Choi, Y., Shim, M., Kim, S. H., Kim, D. K., Jeong, J., Byeon, J., Jang, G., Kim, J., Robson, P., Lee, C., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01571-5 · Cited by 12
Self-citationCecchi, D. D., Jackson, N., Beckham, W., & Chithrani, D. B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020175 · Cited by 9
Small Molecular Immune Modulators as Anticancer Agents
Han, Y., Zhu, L., Wu, W., Zhang, H., Hu, W., Dai, L., & Yang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_22 · Cited by 8
Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy
Chen, S., Qin, F., Wang, M., Wei, Y., Qian, Z., & Wei, X. (2021) · Nano Research · doi:10.1007/s12274-021-3781-5 · Cited by 8
Satkovich, J., Anderson, C. J., Medina, C. B., Ottolini, M., Lukens, J. R., & Kendall, M. M. (2020) · mBio · doi:10.1128/mbio.02588-20 · Cited by 7
Ma, S., Li, F., & Wang, L. (2024) · Cancer Management and Research · doi:10.2147/cmar.s461964 · Cited by 10
Kido, Y., Ando, T., Iga, T., Ema, M., Kubota, Y., & Tai-Nagara, I. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.11.003 · Cited by 6
Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy
Yang, M., Hou, S., Chen, Y., Chen, H., Chu, M., & Liu, S. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03944-1 · Cited by 6
Macrophage-Based Therapeutic Strategies in Hematologic Malignancies
Khalili, S., Zeinali, F., Fard, A. M., Taha, S. R., Naghibi, A. F., Bagheri, K., Zadeh, M. S., Eslami, Y., Fattah, K., Asadimanesh, N., et al. (2023) · Cancers · doi:10.3390/cancers15143722 · Cited by 7
Tritz, R., Hudson, F. Z., Harris, V. K., Ghoshal, P., Singla, B., Lin, H., Csányi, G., & Stansfield, B. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-03750-6 · Cited by 5
Heterogeneity of monocytes in cancer
Zhang, X., Chen, S., Shi, M. K., Lou, J., Huang, Q., Li, C., Huang, Y., & Xu, L. (2025) · American Journal of Cancer Research · doi:10.62347/cutm4281 · Cited by 5
Tojo, M., Horie, H., Koinuma, K., Miyato, H., Tsukui, H., Kaneko, Y., Futoh, Y., Kimura, Y., Takahashi, K., Saito, A., et al. (2022) · Colorectal Disease · doi:10.1111/codi.16167 · Cited by 4
Tamura, A., Inoue, S., Mori, T., Noguchi, J., Nakamura, S., Saito, A., Kozaki, A., Ishida, T., Sadaoka, K., Hasegawa, D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572413 · Cited by 5
Distinct Roles of Monocyte Subsets in Cancer
Cortez, M. A. S., Eilenberg, W. H., Neumayer, C., & Brostjan, C. (2025) · Cells · doi:10.3390/cells14241982 · Cited by 4
Li, J., & Cheng, C. (2024) · 癌症:英文版 · doi:10.1002/cac2.12540 · Cited by 3
Normalization of the tumor vasculature
Klein, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816196-8.00015-1 · Cited by 3
Golubtsova, A. K., Kantysheva, E. B., Novoselova, A. V., & Попугайло, М. В. (2022) · Научное обозрение Медицинские науки (Scientific Review Medical Sciences) · doi:10.17513/srms.1264 · Cited by 6
Lee, I.-G., & Jung, K. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01759-3 · Cited by 4
Self-citationHong, S., Lee, J., Moon, J., Kong, E., Jeon, J., Kim, Y. S., Kim, H., & Kim, P. (2022) · Biomedical Optics Express · doi:10.1364/boe.462269 · Cited by 2
Prognostic impact of circulating monocyte subsets in pediatric solid tumors
Zahran, A. M., Rayan, A., Sayed, H. A. R., Sobhy, A., Solimn, A., & Darwish, A. M. (2019) · Cancer Biomarkers · doi:10.3233/cbm-182212 · Cited by 2
Xie, Y., Shi, Z., Chen, T., Li, H., Fan, M., Xiang, X., & Liu, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567565 · Cited by 4
Intravital microscopy contribution to cancer: From preclinical to human studies
Garcia, D. P. M., Lin, W., Michaelides, L., Quagliano, A., Gabriel, E. M., & Quiñones‐Hinojosa, A. (2025) · Clinical and Translational Discovery · doi:10.1002/ctd2.70051 · Cited by 1
Tumor Microcirculation: Abnormalities and Normalization
Fukumura, D. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_13 · Cited by 1
Self-citationLiang, D., Xue, F., Xie, J., Yang, J., Ni, X., Zhang, J., & Gu, H. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01534-x · Cited by 1
Low‐Dose Bevacizumab Maintains Efficacy With Reduced Adverse Events in Liver Cancer
Lin, P., Teng, W., Hsieh, Y., Wu, T. ‐., Chen, W., Lin, C., Lin, S., & Lin, C. (2026) · Liver International · doi:10.1111/liv.70617 · Cited by 1
Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors
Zhao, Y., Zhang, G., Nie, X., Ren, J., Xu, D., Yan, H., Zhao, J., Tong, L., Zhao, L., & Liu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1803646 · Cited by 3
Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets
Lu, Y., Shao, D., Xiao, Y., Jiang, Y., & Shao, Z. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02851-w · Cited by 5
Ye, X., Tan, S., Huang, W., & Wang, Y. (2023) · Medicine · doi:10.1097/md.0000000000036548 · Cited by 1
Research Progress of Nano-Drugs Remodeling TAMs for Enhancing Cancer Immunotherapy
刘, 湘. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451389 · Cited by 1
Saha, P., Hasib, M. A., Halder, B., Sultana, S., & Rafe, M. R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106589 · Cited by 2
Timpson, P. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735403528.793580079 · Cited by 1
Tumor cell-derived CCL2 promotes chemoresistance via c-Fos in lung adenocarcinomaPreprint
Wang, D., Yang, L., Li, Y., Cao, L., Zhang, K., Lian, J., Shen, Z., Huang, J., Wang, L., & Zhang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-450308/v1
Shan, G., Bi, G., Bian, Y., Besskaya, V., Zeng, D., Zhang, H., Yao, G., Zhang, Y., Fan, H. B., & Zhan, C. (2021) · Research Square · doi:10.21203/rs.3.rs-464643/v1
Tissue-resident myeloid-derived suppressor cells modulate immune homeostasis in healthy adipose.
Stivers, K. B. (2020) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3502
Calderwood, S. K. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734959127.793558900
Wang, Q., Roh, E., Khan, A. U., Dickinson, S. E., Wondrak, G. T., Bode, A. M., Curiel‐Lewandrowski, C. N., & Zhang, T. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.07.021 · Cited by 1
Park, J. A., Wang, L., & Cheung, N.-K. V. (2021) · Figshare · doi:10.6084/m9.figshare.16590464
Qiu, Z., Ji, J., Xu, Y., Zhu, Y., Gao, C., Wang, G., Li, C., Zhang, Y., Zhao, J., Wang, C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19135969
Qiu, Z., Ji, J., Xu, Y., Zhu, Y., Gao, C., Wang, G., Li, C., Zhang, Y., Zhao, J., Wang, C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19135972
Qiu, Z., Ji, J., Xu, Y., Zhu, Y., Gao, C., Wang, G., Li, C., Zhang, Y., Zhao, J., Wang, C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19135975
Mao, X., Cao, X., Qian, L., Gao, M., Zhang, N., Huang, M., Fan, P., Qi, Z., Liu, T., Zhang, H., et al. (2026) · Breast Cancer Research · doi:10.1186/s13058-026-02229-4
Etude de la dynamique des phagocytes mononucléés au cours du processus inflammatoire
Hamon, P. (2017) · theses.fr (ABES) · doi:10.70675/ee1d73beza58cz4dc7z98adz671487b5acaa
Enhancing immune cell trafficking to brain tumors: Recent advances and therapeutic strategies
Tong, Z., Kim, C., Ross, J., & Arvanitis, C. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag075 · Cited by 4
Lemaitre, L. (2020) · theses.fr (ABES) · doi:10.70675/5f2ec192z0a08z4328z9b22z012efd718fc3 · Cited by 1
Xu, L., Wang, X., Lai, X., Li, A., Mao, Y., Wang, X., & Wu, J. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s582999
Liu, C., Zhou, R., Liu, W., Li, R., Xiao, J., Wu, J., Ning, Z., Chen, Z., Qian, C., Zhang, Y., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.011
Immunity and Beyond: Emerging Roles of Monocytes and Macrophages in Cancer
Tomás, A., & Pojo, M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_7
Metadata
- Authors
- Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., Yun, S. H., Langer, R., Anderson, D. G., Padera, T. P., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Duke Medical Center (US)
- Harvard–MIT Division of Health Sciences and Technology (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-07-10
- Volume
- 127
- Issue
- 8
- Pages
- 3039-3051
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531423
- OpenAlex
- W2726768474
- Cited by
- 164
- References
- 75
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 13 · 2023: 10 · 2022: 28 · 2021: 26 · 2020: 25 · 2019: 20 · 2018: 16 · 2017: 6
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- National Institutes of Health (NIH DP2, W81XWH, 1dp2od008780-01, CA126642, CA080124)
- Harvard School of Engineering and Applied Sciences
- National Cancer Institute (CA096915, W81XWH-10-1-0016, R01CA096915, P01CA080124, R00CA137167, R01CA126642, R35CA197743, R01CA208205, R01CA204028)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fractalkine, CX3CR1, anti-VEGF therapy resistance, colorectal cancer, immunosuppression, neutrophil recruitment, CXCL5, IL-10, endothelial cells, monocyte transmigration, siRNA gene therapy, nanoparticle delivery, tumor microenvironment
- MeSH terms
- Intravital Microscopy, CX3C Chemokine Receptor 1, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Agents, Humans, Immunosuppression Therapy, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Monocytes, Neoplasms, Neutrophils, Up-Regulation, Drug Resistance, Neoplasm, Receptors, Chemokine, RNA, Small Interfering, Vascular Endothelial Growth Factor Receptor-2, Cell Line, Tumor, Mice, Nanoparticles, Chemokine CX3CL1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.